Summary of Significant Accounting Policies (Tables)

6 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Summary of Significant Customer Information

Significant customer information is as follows:

	September 30,			March 31,
	2022			2022
Percentage of accounts receivable:
Customer B		95	%		0	%
Customer C		3	%		25	%
Customer F		1	%		19	%
Customer G		0	%		44	%

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Percentage of revenue:
Customer C		23	%		27	%		19	%		20	%
Customer B		20	%		18	%		17	%		19	%

Summary Of Revenue By Category

The following table presents revenue by category:

	Three Months Ended September 30,										Six Months Ended September 30,
	2022					2021					2022					2021
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)										(in thousands, except percentages)
Point in Time
PGS	$	40,110		53	%	$	41,403		75	%	$	79,800		57	%	$	86,426		76	%
Telehealth (1)		9,171		12	%		—		0	%		18,532		13	%		—		0	%
Consumer services		49,281		65	%		41,403		75	%		98,332		70	%		86,426		76	%
Research services		—		0	%		—		0	%		—		0	%		—		0	%
Total (2)		49,281		65	%		41,403		75	%		98,332		70	%		86,426		76	%
Over Time
PGS		4,731		7	%		3,085		6	%		9,216		6	%		5,912		5	%
Telehealth (1)		2,497		3	%		—		0	%		5,020		4	%		—		0	%
Consumer services		7,228		10	%		3,085		6	%		14,236		10	%		5,912		5	%
Research services		19,150		25	%		10,716		19	%		27,604		20	%		22,105		19	%
Total (2)		26,378		35	%		13,801		25	%		41,840		30	%		28,017		24	%
Total Revenue
PGS		44,841		60	%		44,488		81	%		89,016		63	%		92,338		81	%
Telehealth (1)		11,668		15	%		—		0	%		23,552		17	%		—		0	%
Consumer services		56,509		75	%		44,488		81	%		112,568		80	%		92,338		81	%
Research services		19,150		25	%		10,716		19	%		27,604		20	%		22,105		19	%
Total (2)	$	75,659		100	%	$	55,204		100	%	$	140,172		100	%	$	114,443		100	%

(1)There was no telehealth revenue for the three and six months ended September 30, 2021, as the Lemonaid Acquisition closed in November 2021.

(2)There was no Therapeutics revenue for the three and six months ended September 30, 2022 and 2021.

Summary of Revenue by Region based on the Shipping Address of Customers

The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered:

	Three Months Ended September 30,										Six Months Ended September 30,
	2022					2021					2022					2021
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)										(in thousands, except percentages)
United States	$	52,546		69	%	$	38,613		70	%	$	100,655		72	%	$	78,965		69	%
United Kingdom		19,030		25	%		12,335		22	%		31,004		22	%		26,240		23	%
Canada		2,839		4	%		2,748		5	%		5,878		4	%		5,988		5	%
Other regions		1,244		2	%		1,508		3	%		2,635		2	%		3,250		3	%
International		23,113		31	%		16,591		30	%		39,517		28	%		35,478		31	%
Total	$	75,659		100	%	$	55,204		100	%	$	140,172		100	%	$	114,443		100	%

Schedule Of Company Revenue and Adjusted EBITDA by Segment

The Company’s revenue and Adjusted EBITDA by segment is as follows:

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
	(in thousands)						(in thousands)
Segment Revenue
Consumer and Research Services	$	75,659		$	55,204		$	140,172		$	114,443
Total Revenue (1)	$	75,659		$	55,204		$	140,172		$	114,443
Segment Adjusted EBITDA
Consumer and Research Services Adjusted EBITDA	$	2,324		$	(760	)	$	(14,673	)	$	(1,265	)
Therapeutics Adjusted EBITDA		(18,663	)		(18,828	)		(37,128	)		(37,131	)
Unallocated Corporate		(13,316	)		(10,095	)		(27,568	)		(18,563	)
Total Adjusted EBITDA	$	(29,655	)	$	(29,683	)	$	(79,369	)	$	(56,959	)
Reconciliation of net loss to Adjusted EBITDA
Net Loss	$	(66,065	)	$	(16,524	)	$	(155,597	)	$	(58,550	)
Adjustments
Interest (income) expense, net		(1,392	)		(92	)		(1,637	)		(136	)
Other (income) expense, net		687			(3	)		1,122			(17	)
Change in fair value of warrant liabilities		—			(29,828	)		—			(29,294	)
Income tax benefit		(1,271	)		—			(1,525	)		—
Depreciation and amortization		5,152			4,871			10,256			9,508
Amortization of acquired intangible assets		4,267			—			8,582			—
Stock-based compensation expense		28,967			10,427			59,430			20,064
Acquisition-related costs (2)		—			1,466			—			1,466
Total Adjusted EBITDA	$	(29,655	)	$	(29,683	)	$	(79,369	)	$	(56,959	)

(1)There was no Therapeutics revenue for the three and six months ended September 30, 2022 and 2021.

(2)For the three and six months ended September 30, 2021, acquisition-related costs primarily consisted of advisory, legal and consulting fees.

Summary of Customers Accounting for 10% or More of Segment Revenues

Customers accounting for 10% or more of segment revenues were as follows:

	Three Months Ended September 30,								Six Months Ended September 30,
	2022				2021				2022				2021
	(in thousands, except percentages)								(in thousands, except percentages)
Consumer and Research Services Segment Revenue:
Customer C(1)	$	17,057	23	%	$	14,935	27	%	$	26,684	19	%	$	23,447	20	%
Customer B(2)	$	14,925	20	%	$	10,002	18	%	$	23,190	17	%	$	21,212	19	%

(1)Customer C revenues are primarily in the United States.

(2)Customer B revenues are in the U.K.